Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists

Joint Bone Spine. 2011 Dec;78(6):542-4. doi: 10.1016/j.jbspin.2011.05.023. Epub 2011 Jul 30.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / pharmacology*
  • Antirheumatic Agents / therapeutic use*
  • Humans
  • Interleukin-12 / antagonists & inhibitors
  • Interleukin-12 / physiology
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / physiology
  • Interleukin-6 / antagonists & inhibitors
  • Interleukin-6 / physiology
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology
  • Spondylitis, Ankylosing / drug therapy*
  • Spondylitis, Ankylosing / physiopathology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Ustekinumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Interleukin-17
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Interleukin-12
  • secukinumab
  • Ustekinumab
  • tocilizumab